Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1985 Nov;86(3):637–644. doi: 10.1111/j.1476-5381.1985.tb08940.x

Monoaminergic involvement in the pharmacological actions of buspirone.

P Skolnick, B A Weissman, M B Youdim
PMCID: PMC1916732  PMID: 2933109

Abstract

Buspirone, MJ-13805 and MJ-13653 did not produce a '5-hydroxytryptamine (5-HT) syndrome' in rats at doses up to 20 mg kg-1. These drugs were very weak 5-HT uptake blockers (IC50 much greater than 10 microM) compared to drugs such as chlorimipramine. These drugs did not inhibit either monoamine oxidase (MAO)-A or MAO-B. The Ki values for these agents as inhibitors of [3H]-5-HT and [3H]-ketanserin binding to rat frontal cortex or hippocampal membranes were in the microM range, well above the brain concentrations achieved after an oral dose of 25 mg kg-1. Parenterally administered buspirone blocked apomorphine-induced stereotypy, inhibited the 5-HT syndrome elicited by 5-methoxy-N,N-dimethyltryptamine, and delayed the onset of p-chloroamphetamine induced behaviours.

Full text

PDF
637

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Garattini S., Caccia S., Mennini T. Notes on buspirone's mechanisms of action. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):19–24. [PubMed] [Google Scholar]
  2. Glaser T., Traber J. Buspirone: action on serotonin receptors in calf hippocampus. Eur J Pharmacol. 1983 Mar 18;88(1):137–138. doi: 10.1016/0014-2999(83)90404-1. [DOI] [PubMed] [Google Scholar]
  3. Goldberg H. L., Finnerty R. J. The comparative efficacy of buspirone and diazepam in the treatment of anxiety. Am J Psychiatry. 1979 Sep;136(9):1184–1187. doi: 10.1176/ajp.136.9.1184. [DOI] [PubMed] [Google Scholar]
  4. Grahame-Smith D. G. Studies in vivo on the relationship between brain tryptophan, brain 5-HT synthesis and hyperactivity in rats treated with a monoamine oxidase inhibitor and L-tryptophan. J Neurochem. 1971 Jun;18(6):1053–1066. doi: 10.1111/j.1471-4159.1971.tb12034.x. [DOI] [PubMed] [Google Scholar]
  5. Green A. R., Grahame-Smith D. G. Effects of drugs on the processes regulating the functional activity of brain 5-hydroxytryptamine. Nature. 1976 Apr 8;260(5551):487–491. doi: 10.1038/260487a0. [DOI] [PubMed] [Google Scholar]
  6. Hjorth S., Carlsson A. Buspirone: effects on central monoaminergic transmission--possible relevance to animal experimental and clinical findings. Eur J Pharmacol. 1982 Sep 24;83(3-4):299–303. doi: 10.1016/0014-2999(82)90265-5. [DOI] [PubMed] [Google Scholar]
  7. Hyttel J. Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro. Psychopharmacology (Berl) 1978 Dec 15;60(1):13–18. doi: 10.1007/BF00429172. [DOI] [PubMed] [Google Scholar]
  8. Jacobs B. L. An animal behavior model for studying central serotonergic synapses. Life Sci. 1976 Sep 15;19(6):777–785. doi: 10.1016/0024-3205(76)90303-9. [DOI] [PubMed] [Google Scholar]
  9. Kuhn D. M., Wolf W. A., Youdim M. B. 5-Hydroxytryptamine release in vivo from a cytoplasmic pool: studies on the 5-HT behavioural syndrome in reserpinized rats. Br J Pharmacol. 1985 Jan;84(1):121–129. [PMC free article] [PubMed] [Google Scholar]
  10. Leysen J. E., Niemegeers C. J., Van Nueten J. M., Laduron P. M. [3H]Ketanserin (R 41 468), a selective 3H-ligand for serotonin2 receptor binding sites. Binding properties, brain distribution, and functional role. Mol Pharmacol. 1982 Mar;21(2):301–314. [PubMed] [Google Scholar]
  11. Mallat M., Hamon M. Ca2+-guanine nucleotide interactions in brain membranes. I. Modulation of central 5-hydroxytryptamine receptors in the rat. J Neurochem. 1982 Jan;38(1):151–161. doi: 10.1111/j.1471-4159.1982.tb10866.x. [DOI] [PubMed] [Google Scholar]
  12. McMillen B. A., Mattiace L. A. Comparative neuropharmacology of buspirone and MJ-13805, a potential anti-anxiety drug. J Neural Transm. 1983;57(4):255–265. doi: 10.1007/BF01248997. [DOI] [PubMed] [Google Scholar]
  13. Oakley N. R., Jones B. J. Buspirone enhances [3H]flunitrazepam binding in vivo. Eur J Pharmacol. 1983 Mar 4;87(4):499–500. doi: 10.1016/0014-2999(83)90093-6. [DOI] [PubMed] [Google Scholar]
  14. Riblet L. A., Taylor D. P., Eison M. S., Stanton H. C. Pharmacology and neurochemistry of buspirone. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):11–18. [PubMed] [Google Scholar]
  15. Rickels K., Weisman K., Norstad N., Singer M., Stoltz D., Brown A., Danton J. Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry. 1982 Dec;43(12 Pt 2):81–86. [PubMed] [Google Scholar]
  16. Skolnick P., Paul S. M., Weissman B. A. Preclinical pharmacology of buspirone hydrochloride. Pharmacotherapy. 1984 Nov-Dec;4(6):308–314. doi: 10.1002/j.1875-9114.1984.tb03384.x. [DOI] [PubMed] [Google Scholar]
  17. Sloviter R. S., Drust E. G., Connor J. D. Specificity of a rat behavioral model for serotonin receptor activation. J Pharmacol Exp Ther. 1978 Aug;206(2):339–347. [PubMed] [Google Scholar]
  18. Stein L., Belluzzi J. D., Wise C. D. Benzodiazepines: behavioral and neurochemical mechanisms. Am J Psychiatry. 1977 Jun;134(6):665–669. doi: 10.1176/ajp.134.6.665. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES